Abstract Introduction: Adjuvant tamoxifen is the standard therapy for early stage hormone receptor+ breast cancers (BC). Estrogen receptor (ER) and progesterone receptor (PR) analysis is routinely performed by immunohistochemical (IHC) testing on BC specimens to assist in determining hormone receptor status and patient treatment. ER/PR IHC methodologies and guidelines have recently come under review. Many clinical laboratories have opted to use platform specific, ready-to-use (RTU) ER/PR assays provided by three companies: Dako, Leica and Ventana. While each of these companies are using antibodies that were validated on BC clinical outcome series, these platform specific RTU assays have never been directly compared using the same clinical outcome series. We present a systematic comparison of the three platform specific RTU ER/PR assays, using a retrospective BC cohort, to evaluate the concordance and reproducibility of the RTU ER/PR assays, and to assess the ability of the RTU ER assays to predict tamoxifen response. Methods: The Calgary Tamoxifen Cohort is a retrospective database containing demographic, clinical and pathological data for 820 BC patients diagnosed between 1985–2000 at the Tom Baker Cancer Centre (Calgary, Canada). Formalin-fixed paraffin-embedded tissue blocks were available for 511 patients, and replicate 0.6mm cores were taken and built into tissue microarrays (TMAs). The TMAs were stained using the platform specific assays on the DakoLink Plus, Ventana BenchMark Ultra, or Bond-III Leica autostainers. Slides were manually scored by the Allred method. Results: Ventana and Dako had the best concordance for ER (κ=0.90). Substantial agreement was seen for ER staining between Leica and Ventana (κ=0.79), and Dako and Leica (κ=0.66). Agreement was more consistent between the three platforms for PR staining (κ=0.78–0.82). Inter-observer reproducibility was evaluated for all three platforms between three observers: Dako ER (κ=0.80–0.92) and PR (κ=0.69–0.90); Leica ER (κ=0.67–0.83) and PR (κ=0.70–0.89); Ventana ER (κ=0.88–1.00) and PR (κ=0.78–0.94). TMAs were rescored and intra-observer agreement was calculated: Dako ER (κ=1.00) and PR (κ=0.98); Leica ER (κ=0.91) and PR (κ=0.94); Ventana ER (κ=1.00) and PR (κ=0.94). ER Allred scores were dichotomized using current standards and univariate analysis for 5-year disease free survival was performed. All platforms achieved significance with the logrank test and hazard ratio (HR) estimates (p < 0.0001). Cox models were also run to adjust for lymph node status, grade, size and HER2 status. ER status determined by Dako [HR=0.37(0.19–0.74), p = 0.005] and Ventana [HR=0.40(0.18–0.87), p = 0.021] maintained significance, while ER status determined by Leica [HR=0.61(0.31–1.20), p = 0.154] did not. Conclusions: Concordance between RTU assays demonstrated more variation for ER than PR. All assays showed substantial agreement for inter- and intra- observer reproducibility. Although ER RTU assays from all vendors performed as expected in univariate analysis, multivariate models demonstrated differences. Dako and Ventana appeared equivalent in the multivariate analysis, each providing prognostic information, whereas Leica did not achieve independence in this analysis. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-07-10.